Neuroinflammation and Dyskinesia: A Possible Causative Relationship?

Brain Sci

Experimental Neurophysiology Laboratory, IRCCS San Raffaele Roma, 00166 Rome, Italy.

Published: May 2024

Levodopa (L-DOPA) treatment represents the gold standard therapy for Parkinson's disease (PD) patients. L-DOPA therapy shows many side effects, among them, L-DOPA-induced dyskinesias (LIDs) remain the most problematic. Several are the mechanisms underlying these processes: abnormal corticostriatal neurotransmission, pre- and post-synaptic neuronal events, changes in gene expression, and altered plasticity. In recent years, researchers have also suggested non-neuronal mechanisms as a possible cause for LIDs. We reviewed recent clinical and pre-clinical studies on neuroinflammation contribution to LIDs. Microglia and astrocytes seem to play a strategic role in LIDs phenomenon. In particular, their inflammatory response affects neuron-glia communication, synaptic activity and neuroplasticity, contributing to LIDs development. Finally, we describe possible new therapeutic interventions for dyskinesia prevention targeting glia cells.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11118841PMC
http://dx.doi.org/10.3390/brainsci14050514DOI Listing

Publication Analysis

Top Keywords

lids
5
neuroinflammation dyskinesia
4
dyskinesia causative
4
causative relationship?
4
relationship? levodopa
4
levodopa l-dopa
4
l-dopa treatment
4
treatment represents
4
represents gold
4
gold standard
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!